10 th International Congress on Peritoneal Surface Malignancies

Transcription

1 10 th International Congress on Peritoneal Surface Malignancies November 17 19, 2016 Omni Shoreham Hotel Washington, DC Course Director: MedStar Washington Hospital Center Washington, DC American Peritoneal Surface Malignancies MedStar Health 5A5P5M BRAZILIAN SOCIETY OF SURGIC AL ONCOLOGY sso e IASO Indian Association of Surgical Oncology SSO Society of Surgical Oncology

2 Course Description In the past decade, the treatment of peritoneal metastases has gained interest from oncologic communities around the world. During the 1990 s, the first pioneering centers began treating patients with hyperthermic intraperitoneal chemotherapy (HIPEC). Prior to HIPEC, patients were treated with palliative support and only guaranteed a few months to live. Today, if a patient with peritoneal metastases is provided with proper treatment, the survival increases to an average of several years and improved outcomes are reported every day. The mission of the 10 th International Congress on Peritoneal Surface Malignancies (PSOGI 2016) is to provide clinical and scientific information on peritoneal surface malignancies and to create awareness regarding innovative treatments that will improve the quality of life for patients. This two and a half day conference is carefully balanced to cover the wide range of topics on peritoneal metastases. It will feature keynote lectures, didactic sessions, debates, meet the professor sessions with case presentations interspersed where appropriate. Extended discussions with elite panels and extensive audience participation is encouraged at this meeting. Individual paper sessions and abstract poster presentations will also be included in the meeting. Additionally, the program will include two satellite programs on Saturday focusing on peritoneal metastases imaging and pharmacology of chemotherapy treatments. Congress at a Glance WEDNESDAY, NOVEMBER 16 6:00 PM Welcome Reception page 6 THURSDAY, NOVEMBER 17 8:30 AM 10:30 AM Session I: Colorectal Cancer page 6 11:00 AM 1:00 PM Session II: Ovarian Cancer page 7 2:00 PM 4:00 PM Session III: Lecture/Debate page 7 4:30 PM 5:30 PM Session IV: Debate/Cases page 7 6:00 PM Networking Welcome Reception page 7 FRIDAY, NOVEMBER 18 6:30 AM 8:00 AM Session V: Meet the Professor Breakfast Sessions page 8 8:15 AM 9:30 AM Session VI: Gastric Cancer page 10 9:30 AM 10:30 AM Session VII: Registries page 10 11:00 AM 1:00 PM Session VIII: Abstracts/Cases page 11 2:00 PM 4:00 PM Session IX: Lecture/Debate/Cases page 11 4:30 PM 6:30 PM Session X: Lecture/Debate/Cases page 11 7:30 PM Congress Banquet with Historical Video page 11 SATURDAY, NOVEMBER 19 6:30 AM 8:00 AM Session XI: Meet the Professor Breakfast Sessions page 9 8:15 AM 10:30 AM Session XII: New Technologies page 12 11:00 AM 1:00 PM Session XIII: The Future page 12 1:30 PM 7:00 PM Post-Conference Satellite Symposium Option 1 page 13 1:30 PM 7:00 PM Post-Conference Satellite Symposium Option 2 page 14 2

3 Course Information learning objectives Utilize available data to determine optimal treatment options including cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastases (colorectal, gastric cancer, ovarian cancer, appendiceal cancer, peritoneal mesothelioma) Identify quantitative prognostic indicators to select patients who will most likely benefit from cytoreductive surgery with HIPEC Optimize patient care by discussing the use of the appropriate clinical pathways, patient protocols, and surgical procedures Evaluate the potential efficacy of drugs for use in intraperitoneal or intravenous administrations in the treatment of peritoneal metastases with special emphasis on chemotherapy treatments used in the operating room Discuss patient selection, surgical technique and management of standardized HIPEC regiments resulting in improved patient outcomes Distinguish patients at risk for carcinomatosis during early phases target audience This conference is intended for surgical and medical oncologists, surgical oncology nurses, surgical technicians, perfusionists, gastroenterologists, gynecologists, pharmacologists, pathologists, advanced practice clinicians. and other healthcare professionals interested in peritoneal surface oncology. cme accreditation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MedStar Georgetown University Hospital and MedStar Washington Hospital Center. MedStar Georgetown University Hospital is accredited by the ACCME to provide continuing medical education for physicians. credit designation MedStar Georgetown University Hospital designates this live activity for a maximum of 26 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For Nurses For the purpose of recertification, the American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits issued by organizations accredited by the ACCME. Nurses who attend a Category 1 CME certified activity can complete the continuing education hours section of the ANCC Professional Development Record in order to document the courses attended and the hours obtained. 3

4 Faculty course directors MedStar Washington Hospital Center Washington, DC, USA scientific organizing committee Brendan J. Moran, MCh, FRCS, FRCSI The North Hampshire Hospitals Basingstoke, UNITED KINGDOM David Morris, MD St. George Hospital Kogarah, AUSTRALIA Pompiliu Piso, MD, PhD Hospital Barmherzige Brueder Regensburg, GERMANY H. Richard Alexander Jr., MD University of Maryland Medical Center Baltimore, MD, USA Suzanne Alves, CNS Peritoneal Malignancy Institute Basingstoke, UNITED KINGDOM Luca Ansaloni, MD Papa Giovanni XXIII Hospital Bergamo, ITALY Peter H. Cashin, MD, PhD Uppsala University Uppsala, SWEDEN Tom Cecil, BM, DM Hampshire Hospitals Basingstoke, UNITED KINGDOM Wim Ceelen, MD, PhD Ghent University Ghent, BELGIUM David L. Bartlett, MD University of Pittsburgh Medical Center Pittsburgh, PA, USA Beate S. Rau, MD, PhD Charité Campus Mitte University Hospital Berlin, GERMANY Alvaro Arjona-Sanchez, MD, PhD Hospital U. Reina Sofia, Cordoba Cordoba, SPAIN John K. Chan, MD Palo Alto Medical Foundation San Francisco, CA, USA Marcello Deraco, MD Fondazione IRCCS - Istituto Nazionale dei Tumori Milan, ITALY Olivier Glehen, MD, PhD Hospitalier Lyon Sud Lyon, FRANCE Diane Goere, MD, PhD Institute Gustave Roussy Paris, FRANCE Santiago Gonzalez-Moreno, MD, PhD MD Anderson Cancer Center Madrid Madrid, SPAIN Yan Li, MD, PhD Beijing Shijitan Hospital Beijing, CHINA Vic Verwaal, MD Aarhus University Hospital Aarhus, DENMARK Yutaka Yonemura, MD, PhD Kishiwada Tokushukai Hospital Osaka, JAPAN faculty Nita Ahuja, MD Johns Hopkins University Baltimore, MD, USA David S. Alberts, MD University of Arizona Cancer Center Tucson, AZ, USA Naoual Bakrin, MD, PhD Le Centre Hospitalier Lyon Sud Lyon, FRANCE Dario Baratti, MD Fondazione IRCCS - Istituto Nazionale dei Tumori Milan, ITALY Joel M. Baumgartner, MD, MAS, FACS University of California, San Diego San Diego, CA, USA Lana Bijelic, MD INOVA Health System Falls Church, VA, USA Gina Brown, MD, FRCR Royal Marsden NHS Foundation Trust London, UNITED KINGDOM Dennis S. Chi, MD Memorial Sloan Kettering Cancer Center New York, NY, USA Jean-Marc Classe, MD, PhD Institut de Cancérologie de l Ouest Saint-Herblain Nantes, FRANCE Eelco de Bree, MD, PhD University Hospital Heraklion Heraklion, GREECE Ignace H. de Hingh, MD, PhD Catharina Cancer Institute Eindhoven, THE NETHERLANDS Clarisse Dromain, MD, PhD Institute Gustave Roussy Paris, FRANCE 4

5 Jesus Esquivel, MD Cancer Treatment Centers of America Philadelphia, PA, USA Anna Fagotti, MD, PhD Agostino Gemelli University Rome, ITALY Francois-Noel Gilly, MD, PhD Hospices Civils de Lyon Lyon, FRANCE Evgenia A. Halkia, MD Athens General Clinic Athens, GREECE Nader N. Hanna, MD University of Maryland School of Medicine Baltimore, MD, USA Richard A. Hoefer Jr., DO Sentara Surgery Specialists Newport News, VA, USA Charles Honore, MD, PhD Institute Gustave Roussy Paris, FRANCE Marybeth S. Hughes, MD, FACS National Cancer Institute Bethesda, MD, USA James S. Jelinek, MD MedStar Washington Hospital Center Washington, DC, USA Helen M. Kennedy, RN, STN St. George Hospital Sydney, AUSTRALIA Joji Kitayama, MD Jichi Medical University Tokyo, JAPAN Shigeki Kusamura, MD, PhD Fondazione IRCCS - Istituto Nazionale dei Tumori Milan, ITALY Laura A. Lambert, MD University of Massachusetts Medical School Worcester, MA, USA Edward A. Levine, MD Wake Forest University Winston-Salem, NC, USA Gabriel Liberale, MD Institut Jules Bordet Brussels, BELGIUM Faheez Mohamed, MD Peritoneal Malignancy Institute Basingstoke, UNITED KINGDOM Samantha A. Moritz, PA-C MedStar Washington Hospital Center Washington, DC, USA Garrett M. Nash, MD, MPH Memorial Sloan Kettering Cancer Center New York, NY, USA Sang-Yoon Park, MD, PhD National Cancer Center Goyang, REPUBLIC OF KOREA Marc Pocard, MD, PhD Lariboisière Hospital St. Louis Hospital Paris, FRANCE Francois Quenet, MD Institut Du Cancer De Montpellier Montpellier, FRANCE Steven A. Rosenberg, MD, PhD National Cancer Institute Bethesda, MD, USA Pascal Rousset, MD, PhD Centre Hospitalier Lyon Sud Lyon, FRANCE David P. Ryan, MD Massachusetts General Hospital Boston, MA, USA Paolo Sammartino, MD, PhD Sapienza University of Rome Rome, ITALY Armando Sardi, MD, FACS Mercy Medical Center Baltimore, MD, USA John D. Spiliotis, MD, PhD Metaxa Cancer Hospital Pireus, GREECE Pieter J. Tanis, MD, PhD Academic Medical Centre Amsterdam, THE NETHERLANDS Antonios-Apostolos K. Tentes, MD, PhD Metropolitan Hospital Athens, GREECE Kiran K. Turaga, MD, MPH University of Chicago Chicago, IL, USA Kurt Van der Speeten, MD, PhD Ziekenhuis Oost-Limburg Hasselt, BELGIUM Willemien van Driel, MD, PhD Netherlands Cancer Institute- Antoni Van Leeuwenhoek Amsterdam, THE NETHERLANDS Stephanie L. Wethington, MD MedStar Washington Hospital Center Washington, DC, USA Frans A.N. Zoetmulder, MD, PhD Zomba Central Hospital Zomba, MALAWI 5

6 Wednesday, November 16 6:00 PM Registration & Welcome Reception Thursday, November 17 7:00 AM Registration & Breakfast 8:00 AM Welcome Remarks 8:15 AM Welcome Comments from Local Dignitary Steven A. Rosenberg, MD, PhD SESSION I: UPDATE ON CLINICAL TRIALS IN COLORECTAL CANCER Moderators: Marc Pocard, MD, PhD; PROACTIVE PROTOCOLS: 8:30 AM ProphyloCHIP: CRS and HIPEC with Second-Look Surgery Diane Goere, MD, PhD 8:40 AM PRODIGE 7: Adjuvant ± HIPEC for Peritoneal Metastases from Colon Cancer Francois Quenet, MD 8:50 AM COLOPEC: Adjuvant HIPEC for Primary Colon Cancer Pieter J. Tanis, MD, PhD 9:00 AM PROMENADE: Prophylactic HIPEC for Primary Colon Cancer Paolo Sammartino, MD, PhD TREATMENT PROTOCOLS: 9:10 AM ICARuS EPIC FUDR versus HIPEC after Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum with Isolated Peritoneal Metastasis Garrett M. Nash, MD, MPH 9:20 AM Surgery and Oxaliplatin or Mitomycin C in Treating Patients with Tumors of the Appendix Edward A. Levine, MD 9:30 AM Cytoreduction and Intraperitoneal Chemotherapy versus Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis Peter H. Cashin, MD, PhD 9:40 AM COMBATAC: Combined Anticancer Treatment of Advanced Colon Cancer Pompiliu Piso, MD, PhD 9:50 AM Current Status and Future Prospects for Clinical Trials in Peritoneal Metastases from Colorectal Cancer Moderators: Marc Pocard, MD, PhD; Panelists: P. Cashin, D. Goere, E. Levine, G. Nash, P. Piso, F. Quenet, P. Sammartino, P. Tanis 10:30 AM Break 6

7 SESSION II: UPDATE ON CLINICAL TRIALS IN OVARIAN CANCER Moderators: Luca Ansaloni, MD; Dennis S. Chi, MD 11:00 AM CRS and HIPEC in Recurrent Ovarian Cancer John D. Spiliotis, MD, PhD 11:10 AM HIPEC with Carboplatin for Recurrent Ovarian Cancer, Phase II Dennis S. Chi, MD 11:20 AM CHIPOR CRS with or without HIPEC for Relapsed Ovarian Cancer Jean-Marc Classe, MD, PhD 11:30 AM CHORINE CRS with or without HIPEC Upfront for Primary Ovarian Cancer Luca Ansaloni, MD 11:40 AM HORSE CRS with or without HIPEC in Ovarian Cancer Recurrence Anna Fagotti, MD, PhD 11:50 AM Secondary Debulking Surgery ± Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer Willemien van Driel, MD, PhD 12:00 PM Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Armando Sardi, MD, FACS 12:10 PM HIPEC in Primary Ovarian Cancer, NCC Korea Sang-Yoon Park, MD, PhD 12:20 PM Gynecologic Oncology Group 252, IP Carboplatin versus IP Cisplatin John K. Chan, MD 12:30 PM Current Status and Future Prospects for Clinical Trials in Ovarian Cancer Moderators: Luca Ansaloni, MD and Dennis S. Chi, MD Panelists: J. Chan, D. Chi, J. Classe; A. Fagotti, S. Park, A. Sardi, J. Spiliotis, W. van Driel 1:00 PM Lunch & Visit the Posters and Exhibits SESSION III Moderator: David Morris, MD 2:00 PM Keynote Lecture (1): Animal Models: What Can They Tell Us about the Management of Peritoneal Metastases Ignace H. de Hingh, MD, PhD 2:30 PM Debate (1): Adjuvant HIPEC is Superior to Second-look Surgery with HIPEC in High Risk Primary Colorectal Cancer for Peritoneal Metastases Paolo Sammartino, MD, PhD (Pro) vs. Diane Goere, MD, PhD (Con) 3:00 PM Presentation of Best Abstracts (1-4) 4:00 PM Break SESSION IV Moderator: Diane Goere, MD, PhD 4:30 PM Debate (2): CRS and HIPEC is the Standard of Care for Selected Patients with Colorectal Peritoneal Metastases Wim Ceelen, MD, PhD (Pro) vs. David P. Ryan, MD (Con) 5:00 PM Case Presentations (1): Prevention and Treatment of Peritoneal Metastases from Colorectal Cancer Moderators: Dario Baratti, MD; Panelists: D. Bartlett, S. Gonzalez-Moreno, M. Pocard, D. Ryan, V. Verwaal NETWORKING WELCOME RECEPTION 6:00 PM 7

8 Meet the Professor Breakfast Sessions On Friday November 18th and Saturday November 19th, 2016, the 10th International Congress on Peritoneal Surface Malignancies will host (10) morning sessions that will also include a continental breakfast. Each session will highlight a specific topic in a small group setting with internationally renowned leaders in the field. The breakout sessions are listed below. Space is limited; please make sure to select one breakout session per day in your registration to confirm participation. friday, november 18, :30 am 8:00 am 1. Drugs, Doses, and Duration of Treatments to Standardize HIPEC and EPIC for Colorectal, Appendiceal, Gastric, Ovarian, and Peritoneal Mesothelioma Wim Ceelen, MD, PhD; Eelco de Bree, MD, PhD; Kurt Van der Speeten, MD, PhD 2. Molecular Assessment in the Management of Peritoneal Metastases Nita Ahuja, MD; H. Richard Alexander Jr., MD; Edward A. Levine, MD 3. Proactive Management of Colorectal and other Cancers using Adjuvant HIPEC or Second-Look Surgery Tom Cecil, BM, DM; Diane Goere, MD, PhD; Charles Honore, MD, PhD ; Gabriel Liberale, MD; David Morris, MD; Pieter J. Tanis, MD, PhD 4. Starting a New Peritoneal Surface Oncology Program Dario Baratti, MD; Dennis S. Chi, MD; Beate S. Rau, MD, PhD; Vic Verwaal, MD 5. NIPS and Surgery for Gastric Cancer Joji Kitayama, MD; Francois Quenet, MD; Yutaka Yonemura, MD, PhD 6. ESSO/PSOGI Certificate in Peritoneal Surface Oncology Marcello Deraco, MD; Santiago Gonzalez-Moreno, MD, PhD 7. Unusual Diseases are Treated by CRS and HIPEC: How to Select Patients who will Benefit Luca Ansaloni, MD; Lana Bijelic, MD, Marybeth S. Hughes, MD, FACS; 8. Neoadjuvant, Adjuvant and Long-term IP/IV Chemotherapy, HIPEC, EPIC for Ovarian Cancer Naoual Bakrin, MD, PhD; Jean-Marc Classe, MD, PhD; Anna Fagotti, MD, PhD; Evgenia A. Halkia, MD; Sang-Yoon Park, MD, PhD; Willemien van Driel, MD, PhD; Stephanie L. Wethington, MD 9. Pseudomyxoma Peritonei: Natural History and Treatment Yan Li, MD, PhD; Brendan J. Moran, MCh, FRCS, FRCSI 10. Nurses, APCs and Allied Healthcare Professionals: Patient s Journey with Peritoneal Malignancy Part 1 Suzanne Alves, CNS; Helen M. Kennedy, RN, STN; Laura A. Lambert, MD; Samantha A. Moritz, PA Underline = Session Chairperson 8

9 saturday, november 19, :30 am 8:00 am 11. Global Guidelines for Management of Peritoneal Mesothelioma H. Richard Alexander Jr., MD; Marcello Deraco, MD; Kiran K. Turaga, MD, MPH 12. Pseudomyxoma Peritonei: Follow-up and Management of Recurrent Disease Tom Cecil, BM, DM; Nader N. Hanna, MD; John D. Spiliotis, MD, PhD 13. Intraperitoneal Ports: When, Where, Why, How, Always or Never? Lana Bijelic, MD; John K. Chan, MD; Sang-Yoon Park, MD, PhD 14. Peritoneal Metastases from Small Bowel Adenocarcinoma: Results of Treatment Eelco de Bree, MD, PhD; Ignace H. de Hingh, MD, PhD; Yutaka Yonemura, MD, PhD 15. Surgical Complications and Return to the OR Richard A. Hoefer Jr., DO; Pompiliu Piso, MD, PhD; Vic Verwaal, MD 16. Laparoscopy and Peritoneal Surface Malignancy Jesus Esquivel, MD; Olivier Glehen, MD, PhD; Gabriel Liberale, MD; Marc Pocard, MD, PhD; Kurt Van der Speeten, MD, PhD 17. Peritoneal Metastases and Liver Metastases David L. Bartlett, MD; Joel M. Baumgartner, MD, MAS, FACS; Diane Goere, MD, PhD 18. Balancing the Books for CRS and HIPEC in a Diminishing Economy, a Global Exploration Wim Ceelen, MD, PhD; Brendan J. Moran, MCh, FRCS, FRCSI; Garrett M. Nash, MD, MPH 19. Consensus Regarding Concerning Radiologic Features Used to Select Patients for CRS and HIPEC Gina Brown, MD, FRCR; Clarisse Dromain, MD, PhD; James S. Jelinek, MD; Armando Sardi, MD, FACS; 20. Nurses, APCs and Allied Healthcare Professionals: Patient s Journey with Peritoneal Malignancy Part 2 Suzanne Alves, CNS; Helen M. Kennedy, RN, STN; Faheez Mohamed, MD; Samantha A. Moritz, PA Underline = Session Chairperson Call for Abstracts The 10th International Congress on Peritoneal Surface Malignancies (PSOGI 2016) aims at improving the knowledge, treatment and outcome regarding peritoneal surface malignancies. The Scientific Organizing Committee requests participants to submit an abstract to present at the PSOGI 2016 conference. In order to promote multidisciplinary discussions during the conference, all involved disciplines such as surgery, radiology, medical oncology, pathology, and pharmacology are encouraged to submit abstracts to the program. PSOGI 2016 intends to create sufficient room for papers and posters to be presented. Selected abstracts will be incorporated into the plenary sessions for oral presentation. recognition Selected authors will be asked to provide an abstract poster at the meeting, November 17-19, All abstracts will be published in the official PSOGI 2016 program book. submission details Abstracts must be submitted electronically at by August 1, All abstract submitters will be notified of acceptance status no later than September 2, If you have any questions, please call or send an to psogi2016@gmail.com. For categories and information regarding rules and regulations, please visit 9

10 Friday, November 18 SESSION V: MEET THE PROFESSOR BREAKFAST SESSIONS 6:30 AM Registration and Meet the Professor Breakfast Sessions (See page 8 for more Information) SESSION VI: UPDATE ON CLINICAL TRIALS IN GASTRIC CANCER Moderators: Yan Li, MD, PhD; Beate S. Rau, MD, PhD 8:15 AM Opening Comments and Presentation of the Events of the Day 8:30 AM GastriCHIP Gastrectomy ± HIPEC as Adjuvant for Primary Gastric Cancer Olivier Glehen, MD, PhD 8:40 AM NIPOX Adjuvant Intraperitoneal Oxaliplatin for Gastric Cancer with Peritoneal Metastases Francois Quenet, MD 8:50 AM GASTRIPEC Cytoreductive Surgery (CRS) with/without HIPEC in Gastric Cancer with Peritoneal Carcinomatosis Beate S. Rau, MD, PhD 9:00 AM Phoenix GC Neoadjuvant Intraperitoneal and Systemic Chemotherapy (NIPS) for Gastric Cancer with Peritoneal Metastases Joji Kitayama, MD 9:10 AM Current Status and Future Prospects for Clinical Trials in Gastric Cancer Moderators: Yan Li, MD, PhD; Beate S. Rau, MD, PhD Panelists: O. Glehen, J. Kitayama, F. Quenet, P. Sugarbaker SESSION VII: UPDATE ON INTERNATIONAL PERITONEAL METASTASES REGISTRIES Moderators: Pompiliu Piso, MD, PhD; Kiran K. Turaga, MD, MPH 9:30 AM International Registry on Peritoneal Mesothelioma Shigeki Kusamura, MD, PhD 9:40 AM Big RENAPE including Rare Diseases Treated with CRS and HIPEC Diane Goere, MD, PhD 9:50 AM German Registry Pompiliu Piso, MD, PhD 10:00 AM Dutch Registry Vic Verwaal, MD 10:10 AM Current Status and Future Prospects for Peritoneal Metastases Registries Moderators: Pompiliu Piso, MD, PhD; Kiran K. Turaga, MD, MPH Panelists: J. Esquivel, D. Goere, S. Kusamura, M. Pocard, V. Verwaal 10:30 AM Break 10

11 SESSION VIII Moderator: Beate S. Rau, MD, PhD 11:00 AM Presentation of Best Abstracts (5-8) Yutaka Yonemura, MD, PhD 12:00 PM Case Presentations (2): Peritoneal Metastases from Gastric Cancer Moderators: Beate S. Rau, MD, PhD; Panelists: O. Glehen, N. Hanna, J. Kitayama, Y. Yonemura 1:00 PM Lunch & Visit the Posters and Exhibits SESSION IX Moderator: Yutaka Yonemura, MD, PhD 2:00 PM Keynote Lecture (2): Current Treatment Options for Management of Gastric Cancer with Peritoneal Metastases Joji Kitayama, MD 2:30 PM Debate (3): Recurrent Ovarian Cancer: CRS and HIPEC is a Reasonable Treatment Option Now in Selected Patients Naoual Bakrin, MD, PhD (Pro) vs. Stephanie L. Wethington, MD (Con) 3:00 PM Case Presentations (3): CRS and HIPEC for Unusual Diseases Moderators: ; Vic Verwaal, MD Panelists: D. Bartlett, E. de Bree, M. Deraco, D. Goere, A. Tentes 4:00 PM Break SESSION X Moderator: Yan Li, MD, PhD 4:30 PM Keynote Lecture (3): Progress in the Management of Primary and Recurrent Ovarian Cancer in Cordoba, Spain Alvaro Arjona-Sanchez, MD, PhD 5:00 PM Debate (4): Pharmacology and Clinical Data Show that Mitomycin C not 5-FU and High Dose Oxaliplatin is the Current Standard of Care for Peritoneal Metastases from Colon Cancer Joel M. Baumgartner, MD, MAS, FACS (Pro) vs. Olivier Glehen, MD, PhD (Con) 5:30 PM Case Presentations (4): The Prevention and Treatment of Peritoneal Metastases from Ovarian Cancer Moderators: Anna Fagotti, MD, PhD; Panelists: L. Ansaloni, D. Chi, J. Spiliotis, W. van Driel, S. Wethington 6:30 PM Closing Remarks CONGRESS BANQUET WITH HISTORICAL VIDEO 7:30 PM Comments by Francois-Noel Gilly, MD, PhD and Frans A.N. Zoetmulder, MD, PhD Presentation of Certificates for European School of Peritoneal Surface Oncology 11

12 Saturday, November 19 SESSION XI: MEET THE PROFESSOR BREAKFAST SESSIONS 6:30 AM Registration and Meet the Professor Breakfast Sessions (See page 9 for more Information) SESSION XII: NEW TECHNOLOGIES TO OPTIMIZE MANAGEMENT OF PERITONEAL SURFACE MALIGNANCY* Moderator: David L. Bartlett, MD 8:15 AM Opening Comments and Presentation of the Events of the Day 8:30 AM Keynote Lecture (4): Genomic Medicine as it Involves Peritoneal Metastases Nita Ahuja, MD 9:00 AM Preoperative Assessments Jesus Esquivel, MD 9:20 AM Pressurized Intraperitoneal Chemotherapy (PIPAC) Marc Pocard, MD, PhD 9:30 AM Multi-Detector CT to Identify Poor Prognostic Factors in Primary Colorectal Cancer Gina Brown, MD, FRCR 10:00 AM Keynote Lecture (5): Bidirectional Adjuvant Normothermic Chemotherapy (BANC) Long-Term for Management of Ovarian Cancer John K. Chan, MD 10:30 AM Break SESSION XIII: THE FUTURE IS NOW* Moderator: H. Richard Alexander Jr., MD 11:00 AM Keynote Lecture (6): 90% of the Adverse Outcomes Occur in 10% of Patients. Can We Identify the High Risk Groups? Charles Honore, MD, PhD 11:30 AM Case Presentations (5): Prevention and Treatment of Peritoneal Metastases from Appendiceal Cancer Moderators: H. Richard Alexander Jr., MD; Panelists: D. Bartlett, S. Gonzalez-Moreno, B. Moran, D. Morris, P. Tanis 12:30 PM 10 Take Home Messages Santiago Gonzalez-Moreno, MD, PhD 12:45 PM Closing Remarks and Looking Ahead to PSOGI Congress 2018 in Paris Olivier Glehen; MD, PhD, Diane Goere, MD, PhD; Marc Pocard, MD, PhD; 1:00 PM Adjourn ( mina um.. - * In collaboration with the Society of Surgical Oncology 12

13 Saturday Post-Conference Satellite Symposia SATELLITE SYMPOSIUM (OPTION 1) Pharmacology of Chemotherapy Treatments for Peritoneal Metastases: Optimizing and Augmenting HIPEC This satellite symposium will describe the pharmacodynamics and pharmacokinetics of chemotherapy administered with heat in the operating room. Additionally, novel approaches to intraoperative and long-term combined intraperitoneal and systemic chemotherapy will be investigated. Exploration of ovarian cancer molecular agents for intraperitoneal administration will also take place. The program will include ample time for questions and faculty will provide key recommendations for a standardized chemotherapy regimens for peritoneal metastases. SESSION I Moderators: Joji Kitayama, MD; Kurt Van der Speeten, MD, PhD 1:30 PM Pharmacodynamics of Intraperitoneal Chemotherapy Wim Ceelen, MD, PhD 2:00 PM Pharmacokinetics of Chemotherapy Delivery by PIPAC Marc Pocard, MD, PhD 2:30 PM Novel Approaches to Intraperitoneal Drug Delivery David Morris, MD 3:00 PM Long-Term IP/IV Chemotherapy for Ovarian Cancer: Rationale and Pharmacology John K. Chan, MD 3:30 PM Questions & Discussion Moderators: Joji Kitayama, MD; Kurt Van der Speeten, MD, PhD Panelists: W. Ceelen, J. Chan, D. Morris, M. Pocard 4:00 PM Break SESSION II Moderator: David Morris, MD; Marc Pocard, MD, PhD 4:30 PM Pharmacology of Intraperitoneal Chemotherapy for Ovarian Cancer David S. Alberts, MD 5:00 PM Molecular Agents for Intraperitoneal Administration Olivier Glehen, MD, PhD 5:30 PM Nanomicellar Drugs for Intraperitoneal Administration Joji Kitayama, MD 6:00 PM Knowing What We Know Now, the Optimal Perioperative Chemotherapy Regimens are Kurt Van der Speeten, MD, PhD 6:30 PM Questions & Discussion Moderator: David Morris, MD; Marc Pocard, MD, PhD Panelists: D. Alberts, O. Glehen, J. Kitayama, K. Van der Speeten 7:00 PM Adjourn 13

14 Saturday Post-Conference Satellite Symposia SATELLITE SYMPOSIUM (OPTION 2) Peritoneal Metastases Imaging Through a collaboration of an international planning team to standardize the technology and terminology for imaging peritoneal metastases, this symposium will explore the clinical utility of radiologic studies to select patients who will benefit from the surgical treatment of peritoneal metastases. SESSION I Moderators: Clarisse Dromain, MD, PhD; James S. Jelinek, MD 1:30 PM An Initial Attempt to Standardize a Best Technology of CT, MRI, PET for Peritoneal Metastases Clarisse Dromain, MD, PhD 2:00 PM Formulating a Lexicon of Concerning Radiologic Features James S. Jelinek, MD 2:30 PM Description of Peritoneal Metastases by CT Gina Brown, MD, FRCR 3:00 PM Description of Peritoneal Metastases by MRI Pascal Rousset, MD, PhD 3:30 PM Questions & Discussion Moderators: Clarisse Dromain, MD, PhD; James S. Jelinek, MD Panelists: G. Brown, P. Rousset 4:00 PM Break SESSION II Moderator: Clarisse Dromain, MD, PhD; James S. Jelinek, MD 4:30 PM Optical Imaging for Detection of Peritoneal Metastases Gabriel Liberale, MD 5:00 PM Using Radiology to Define High Risk for Peritoneal Metastases in Primary Gastrointestinal Cancer, Colon, Gastric, and Pancreas Gina Brown, MD, FRCR 5:35 PM Peritoneal Metastases: Their Associated Clinical Features- Can PET be of Help? Clarisse Dromain, MD, PhD 6:00 PM Is There a Minimal Required Report for Peritoneal Metastases? Pascal Rousset, MD, PhD 6:30 PM Questions & Discussion Moderator: Clarisse Dromain, MD, PhD; James S. Jelinek, MD Panelists: G. Brown, G. Liberale, P. Rousset 7:00 PM Adjourn 14

15 Registration Information registration fees NOW through September 1, 2016 $500 Physician $350 Residents/Fellow $350 Advanced Practice Clinician $350 Nurse $350 Allied Health Professional September 2 through November 15, 2016* $700 Physician $550 Residents/Fellow $550 Advanced Practice Clinician $550 Nurse $550 Allied Health Professional *An additional $100 will be added to onsite registrations November Post-Conference Satellite Symposia (Additional Fee) $150 Physician $100 Residents/Fellow $100 Advanced Practice Clinician $100 Allied Health Professional Please visit our secure website at to register to attend. We are unable to accept registrations or cancellations by telephone. All registrations will be confirmed by only. Please use an address that you check regularly. If you have questions regarding registration or do not receive an confirmation of your registration within 1-2 business days, please contact us at psogi2016@gmail.com or cancellation policy Cancellations made in writing by Friday, September 30, 2016 will be subject to a 50% penalty. No refunds will be given after September 30, Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, MedStar Health will refund the registration fee, but is not responsible for any travel costs. Please call or psogi2016@gmail.com if you any questions or need any additional information. venue information Omni Shoreham Hotel 2500 Calvert Street, NW, Washington, DC room block Room Block Rate: $239 night plus applicable tax, single or double occupancy Please call Omni Reservations at THE-OMNI ( ) to book your room today! Reservations can also be made online by visiting psogi2016. When making reservations by phone, please indicate that you are a part of the 10th International Congress on Peritoneal Surface Malignancies Group. Our preferred discount room block is available Monday, November 14th, 2016 through Tuesday, November 22nd, Reservation requests received after that date will be based on availabilty at the hotel's prevailing rates. The cut-off date for making reservations is Friday, October 21,

16 10 th International Congress on Peritoneal Surface Malignancies November 17 19, 2016 Omni Shoreham Hotel Washington, DC 3007 Tilden Street, NW, Suite 3N Washington, DC NON-PROFIT ORG. U.S. POSTAGE PAID MEDSTAR WASHINGTON HOSPITAL CENTER Course Director: MedStar Washington Hospital Center Washington, DC MedStar Health